Typhim Vi Stungulyf, lausn 25 míkróg/0,5 ml أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

typhim vi stungulyf, lausn 25 míkróg/0,5 ml

sanofi pasteur* - salmonella typhi vi antigen - stungulyf, lausn - 25 míkróg/0,5 ml

ALPHA JECT 5-3 Stungulyf, fleyti أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

alpha ject 5-3 stungulyf, fleyti

pharmaq as* - aeromonas salmonicida subsp. salmonicida; vibrio salmonicida; listonella anguillarum serotype o1; listonella anguillarum serotype o2a; moritella viscosa - stungulyf, fleyti

Alpha Ject 3000 Stungulyf, fleyti أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

alpha ject 3000 stungulyf, fleyti

pharmaq as* - aeromonas salmonicida subs. salmonicida al 2017; vibrio anguillarum serotype o1 al 112; vibrio anguillarum serotype 02 al 104 - stungulyf, fleyti

Alpha Ject micro 5 Stungulyf, fleyti ein. أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

alpha ject micro 5 stungulyf, fleyti ein.

pharmaq as* - aeromonas salmonicida subs. salmonicida al 2017; vibrio anguillarum serotype o1 al 112; vibrio anguillarum serotype 02 al 104; moritella viscosa; vibrio salmonicida - stungulyf, fleyti - ein.

Shingrix الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

shingrix

glaxosmithkline biologicals sa - recombinant varicella zoster virus glycoprotein e - ristil - bóluefni - shingrix is indicated for prevention of herpes zoster (hz) and post-herpetic neuralgia (phn), in:adults 50 years of age or older;adults 18 years of age or older at increased risk of hz. notkun shingrix ætti að vera í samræmi við opinbera tillögur.

Enterisol Ileitis vet. (Enterisol Ileitis) Frostþurrkað mixtúruduft og leysir, dreifa أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

enterisol ileitis vet. (enterisol ileitis) frostþurrkað mixtúruduft og leysir, dreifa

boehringer ingelheim vetmedica gmbh - lawsonia intracellularis - frostþurrkað mixtúruduft og leysir, dreifa

Arexvy الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

arexvy

glaxosmithkline biologicals s.a.  - respiratory syncytial virus recombinant glycoprotein f stabilised in the pre-fusion conformation (rsvpref3) produced in chinese hamster ovary (cho) cells by recombinant dna technology - sýkingar af völdum sýklalyfja - bóluefni - arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (lrtd) caused by respiratory syncytial virus in adults 60 years of age and older. notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.

Crestor Filmuhúðuð tafla 5 mg أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

crestor filmuhúðuð tafla 5 mg

astrazeneca a/s - rosuvastatinum kalsíum - filmuhúðuð tafla - 5 mg

Crestor Filmuhúðuð tafla 40 mg أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

crestor filmuhúðuð tafla 40 mg

astrazeneca a/s - rosuvastatinum kalsíum - filmuhúðuð tafla - 40 mg

Crestor Filmuhúðuð tafla 20 mg أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

crestor filmuhúðuð tafla 20 mg

astrazeneca a/s - rosuvastatinum kalsíum - filmuhúðuð tafla - 20 mg